sales@fnfresearch.comTel: +86 21 80360450 | USA: +1-347-989-3985

Search Market Research Report

Home / Healthcare / Type 1 Diabetes

Type 1 Diabetes Market By Insulin Analog (Rapid-Acting Insulin Analogs, Long-Acting Insulin Analogs, and Premix Insulin Analogs): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026

  • Publish On: Jun-2020
  • Total Pages: 178
  • Report Code: FAF-1256
  • Base Year: 2019
  • Format:

Industry Insights

This specialized and expertise oriented industry research report scrutinizes the technical and commercial business outlook of the type 1 diabetes industry. The report analyzes and declares the historical and current trends analysis of the type 1 diabetes industry and subsequently recommends the projected trends anticipated to be observed in the type 1 diabetes market during the upcoming years.

The type 1 diabetes market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire type 1 diabetes market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Million) from FY 2016 – 2026.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the type 1 diabetes industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the type 1 diabetes industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the type 1 diabetes market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the type 1 diabetes industry. The type 1 diabetes market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the type 1 diabetes sector. Key strategic developments in the type 1 diabetes market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the type 1 diabetes market are appropriately highlighted in the report.

The type 1 diabetes market research report delivers an acute valuation and taxonomy of the type 1 diabetes industry by practically splitting the market on the basis of different types, category, and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the type 1 diabetes industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Further, country-wise data for the type 1 diabetes industry is provided for the leading economies of the world.

Diabetes is a defect in metabolism in the pancreas which results in hyperglycemia. Type 1 diabetes also known as insulin-dependent diabetes mellitus or juvenile diabetes is a condition where there is an immune response against insulin-producing beta cells of the pancreas. In type 1 diabetes, there has to be an external supply of insulin hence called insulin-dependent diabetes mellitus. The most severe form of diabetes leads to the early destruction of organs. A person can prevent type 2 diabetes by avoiding sugar enrich food products in the diet, however, such prevention is not possible when it comes to type 1 diabetes. The immune system strikes colonies of cells in the body that would normally generate insulin, called islets, blocking or slowing down insulin supply.

In recent years, there has been a steady rise in the number of type 1 diabetic patients. Type 1 diabetes is treated with injectable insulin and this type of insulin can't be treated with oral supplements. Injectable insulin use an insulin pen to inject insulin under the skin. Type 1 diabetic patients have to mainly rely on injectable insulin. Such dependency of patients has driven the global type 1 diabetes insulin market.

The type 1 diabetes market is segmented based on drug type and region. On the basis of insulin analogs, the market is classified into rapid-acting insulin analogs, long-acting insulin analogs, and premix insulin analogs.

Some of the essential players operating in the type 1 diabetes market, but not restricted to include Eli Lilly and Company, Bayer Pharmaceuticals, Sanofi, Novo Nordisk, AstraZeneca PLC., XOMA Corp., DiaVacs Inc., B.BraunMelsungen AG, Biodel Inc., Macrogenics Inc., Takeda Pharmaceutical, and Others.

The taxonomy of the type 1 diabetes industry by its scope and segmentation is as follows:

Global Type 1 Diabetes Market: By Insulin Analog Segmentation Analysis

  • Rapid-Acting Insulin Analogs
  • Long-Acting Insulin Analogs
  • Premix Insulin Analogs

Global Type 1 Diabetes Market: Regional Segmentation Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

KEY REPORT POINTERS & HIGHLIGHTS:

  • Statistically Validated Analysis of Historical, Current, and Projected Industry Trends with Authenticated Market Sizes Information and Data in terms of Value and Volume, wherever applicable
  • Direct and Indirect Factors that Impacted the Industry as well Projected Rationales expected to affect the industry going forward
  • Micro, Meso, Macro, and In-Depth Analysis of Technically relevant and Commercially viable Segments and Sub-segments of the Market
  • Historical and Projected Company / Vendor / OEM / Supplier Market Shares, Competitive Landscape, and Player Positioning Data
  • Historical and Current Demand (Consumption) and Supply (Production) Scenarios as well as Projected Supply-Demand Scenario Analysis
  • Detailed List of Key Buyers and End-Users (Consumers) analyzed as per Regions and Applications
  • Value Chain and Supply Chain Analysis along with Horizontal and Vertical Integration Scenarios
  • Manufacturing and Production Cost Structure Analysis including Labor Cost, Raw Material Expenses, and Other Manufacturing Expenses, wherever relevant
  • Overview of Key Marketing Strategies and Key Sales Channels Adopted in the Market
  • Market Attractiveness Analysis and Key Investment Opportunity Analysis in the Market going forward
  • Technological Roadmap, Patents Analysis, Potential Substitutes, and Technical Analysis
  • The professionally substantiated market research report study is calculated, constructed, and assembled by implementing a Robust Research Methodology. The Triangular Process comprises a buoyant mix of Exhaustive Primary Research (focused interviews, questionnaires, and ad-hoc surveys) and Extended Secondary Research (paid external databases, proprietary in-house database, and publically-available validated sources), where it is finally triangulated and validated through in-house industry experts, industry leaders, and independent consultants through a tri-level quality check practice.

Table of Content

  1. CHAPTER 1. Executive Summary
  2. CHAPTER 2. Type 1 Diabetes market – Insulin Analog Analysis
    1. 2.1. Global Type 1 Diabetes Market–Insulin Analog Overview
    2. 2.2. Global Type 1 Diabetes MarketShare, by Insulin Analog, 2019 & 2026 (USD Million)
    3. 2.3. Rapid-Acting Insulin Analogs
      1. 2.3.1. Global Rapid-Acting Insulin Analogs Type 1 Diabetes Market,2016-2026 (USD Million)
    4. 2.4. Long-Acting Insulin Analogs
      1. 2.4.1. Global Long-Acting Insulin Analogs Type 1 Diabetes Market,2016-2026 (USD Million)
    5. 2.5. Premix Insulin Analogs
      1. 2.5.1. Global Premix Insulin Analogs Type 1 Diabetes Market,2016-2026 (USD Million)
  3. CHAPTER 3. Type 1 Diabetes market – Regional Analysis
    1. 3.1. Global Type 1 Diabetes MarketRegional Overview
    2. 3.2. Global Type 1 Diabetes MarketShare, by Region, 2019 & 2026 (Value)
    3. 3.3. North America
      1. 3.3.1. North America Type 1 Diabetes Market size and forecast, 2016-2026
      2. 3.3.2. North America Type 1 Diabetes Market, by Country, 2019 & 2026 (USD Million)
      3. 3.3.3. North America Type 1 Diabetes Market, by Insulin Analog, 2016-2026
        1. 3.3.3.1. North America Type 1 Diabetes Market, by Insulin Analog, 2016-2026 (USD Million)
      4. 3.3.4. U.S.
        1. 3.3.4.1. U.S. Market size and forecast, 2016-2026 (USD Million)
      5. 3.3.5. Canada
        1. 3.3.5.1. Canada Market size and forecast, 2016-2026 (USD Million)
    4. 3.4. Europe
      1. 3.4.1. Europe Type 1 Diabetes Market size and forecast, 2016-2026
      2. 3.4.2. Europe Type 1 Diabetes Market, by Country, 2019 & 2026 (USD Million)
      3. 3.4.3. Europe Type 1 Diabetes Market, by Insulin Analog, 2016-2026
        1. 3.4.3.1. Europe Type 1 Diabetes Market, by Insulin Analog, 2016-2026 (USD Million)
      4. 3.4.4. Germany
        1. 3.4.4.1. Germany Market size and forecast, 2016-2026 (USD Million)
      5. 3.4.5. France
        1. 3.4.5.1. France Market size and forecast, 2016-2026 (USD Million)
      6. 3.4.6. U.K.
        1. 3.4.6.1. U.K. Market size and forecast, 2016-2026 (USD Million)
      7. 3.4.7. Italy
        1. 3.4.7.1. Italy Market size and forecast, 2016-2026 (USD Million)
      8. 3.4.8. Spain
        1. 3.4.8.1. Spain Market size and forecast, 2016-2026 (USD Million)
      9. 3.4.9. Rest of Europe
        1. 3.4.9.1. Rest of Europe Market size and forecast, 2016-2026 (USD Million)
    5. 3.5. Asia Pacific
      1. 3.5.1. Asia Pacific Type 1 Diabetes Market size and forecast, 2016-2026
      2. 3.5.2. Asia Pacific Type 1 Diabetes Market, by Country, 2019 & 2026 (USD Million)
      3. 3.5.3. Asia Pacific Type 1 Diabetes Market, by Insulin Analog, 2016-2026
        1. 3.5.3.1. Asia Pacific Type 1 Diabetes Market, by Insulin Analog, 2016-2026 (USD Million)
      4. 3.5.4. China
        1. 3.5.4.1. China Market size and forecast, 2016-2026 (USD Million)
      5. 3.5.5. Japan
        1. 3.5.5.1. Japan Market size and forecast, 2016-2026 (USD Million)
      6. 3.5.6. India
        1. 3.5.6.1. India Market size and forecast, 2016-2026 (USD Million)
      7. 3.5.7. South Korea
        1. 3.5.7.1. South Korea Market size and forecast, 2016-2026 (USD Million)
      8. 3.5.8. South-East Asia
        1. 3.5.8.1. South-East Asia Market size and forecast, 2016-2026 (USD Million)
      9. 3.5.9. Rest of Asia Pacific
        1. 3.5.9.1. Rest of Asia Pacific Market size and forecast, 2016-2026 (USD Million)
    6. 3.6. Latin America
      1. 3.6.1. Latin America Type 1 Diabetes Market size and forecast, 2016-2026
      2. 3.6.2. Latin America Type 1 Diabetes Market, by Country, 2019 & 2026 (USD Million)
      3. 3.6.3. Latin America Type 1 Diabetes Market, by Insulin Analog, 2016-2026
        1. 3.6.3.1. Latin America Type 1 Diabetes Market, by Insulin Analog, 2016-2026 (USD Million)
      4. 3.6.4. Brazil
        1. 3.6.4.1. Brazil Market size and forecast, 2016-2026 (USD Million)
      5. 3.6.5. Mexico
        1. 3.6.5.1. Mexico Market size and forecast, 2016-2026 (USD Million)
      6. 3.6.6. Rest of Latin America
        1. 3.6.6.1. Rest of Latin America Market size and forecast, 2016-2026 (USD Million)
    7. 3.7. The Middle-East and Africa
      1. 3.7.1. The Middle-East and Africa Type 1 Diabetes Market size and forecast, 2016-2026
      2. 3.7.2. The Middle-East and Africa Type 1 Diabetes Market, by Country, 2019 & 2026 (USD Million)
      3. 3.7.3. The Middle-East and Africa Type 1 Diabetes Market, by Insulin Analog, 2016-2026
        1. 3.7.3.1. The Middle-East and Africa Type 1 Diabetes Market, by Insulin Analog, 2016-2026 (USD Million)
      4. 3.7.4. GCC Countries
        1. 3.7.4.1. GCC Countries Market size and forecast, 2016-2026 (USD Million)
      5. 3.7.5. South Africa
        1. 3.7.5.1. South Africa Market size and forecast, 2016-2026 (USD Million)
      6. 3.7.6. Rest of Middle-East Africa
        1. 3.7.6.1. Rest of Middle-East Africa Market size and forecast, 2016-2026 (USD Million)
  4. CHAPTER 4. Type 1 Diabetes market – Competitive Landscape
    1. 4.1. Competitor Market Share – Revenue
    2. 4.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    3. 4.3. Strategic Development
      1. 4.3.1. Acquisitions and Mergers
      2. 4.3.2. New Products
      3. 4.3.3. Research & Development Activities
  5. CHAPTER 5. Company Profiles
    1. 5.1. Eli Lilly and Company
      1. 5.1.1. Company Overview
      2. 5.1.2. Eli Lilly and Company Revenue and Gross Margin
      3. 5.1.3. Product portfolio
      4. 5.1.4. Recent initiatives
    2. 5.2. Bayer Pharmaceuticals
      1. 5.2.1. Company Overview
      2. 5.2.2. Bayer Pharmaceuticals Revenue and Gross Margin
      3. 5.2.3. Product portfolio
      4. 5.2.4. Recent initiatives
    3. 5.3. Sanofi
      1. 5.3.1. Company Overview
      2. 5.3.2. Sanofi Revenue and Gross Margin
      3. 5.3.3. Product portfolio
      4. 5.3.4. Recent initiatives
    4. 5.4. Novo Nordisk
      1. 5.4.1. Company Overview
      2. 5.4.2. Novo Nordisk Revenue and Gross Margin
      3. 5.4.3. Product portfolio
      4. 5.4.4. Recent initiatives
    5. 5.5. AstraZeneca PLC.
      1. 5.5.1. Company Overview
      2. 5.5.2. AstraZeneca PLC. Revenue and Gross Margin
      3. 5.5.3. Product portfolio
      4. 5.5.4. Recent initiatives
    6. 5.6. XOMA Corp.
      1. 5.6.1. Company Overview
      2. 5.6.2. XOMA Corp. Revenue and Gross Margin
      3. 5.6.3. Product portfolio
      4. 5.6.4. Recent initiatives
    7. 5.7. DiaVacs Inc.
      1. 5.7.1. Company Overview
      2. 5.7.2. DiaVacs Inc. Revenue and Gross Margin
      3. 5.7.3. Product portfolio
      4. 5.7.4. Recent initiatives
    8. 5.8. B.BraunMelsungen AG
      1. 5.8.1. Company Overview
      2. 5.8.2. B.BraunMelsungen AG Revenue and Gross Margin
      3. 5.8.3. Product portfolio
      4. 5.8.4. Recent initiatives
    9. 5.9. Biodel Inc.
      1. 5.9.1. Company Overview
      2. 5.9.2. Biodel Inc. Revenue and Gross Margin
      3. 5.9.3. Product portfolio
      4. 5.9.4. Recent initiatives
    10. 5.10. Macrogenics Inc.
      1. 5.10.1. Company Overview
      2. 5.10.2. Macrogenics Inc. Revenue and Gross Margin
      3. 5.10.3. Product portfolio
      4. 5.10.4. Recent initiatives
    11. 5.11. Takeda Pharmaceutical
      1. 5.11.1. Company Overview
      2. 5.11.2. Takeda Pharmaceutical Revenue and Gross Margin
      3. 5.11.3. Product portfolio
      4. 5.11.4. Recent initiatives
  6. CHAPTER 6. Type 1 Diabetes — Industry Analysis
    1. 6.1. Type 1 Diabetes Market – Key Trends
      1. 6.1.1. Market Drivers
      2. 6.1.2. Market Restraints
      3. 6.1.3. Market Opportunities
    2. 6.2. Value Chain Analysis
    3. 6.3. Technology Roadmap and Timeline
    4. 6.4. Type 1 Diabetes Market – Attractiveness Analysis
      1. 6.4.1. By Insulin Analog
      2. 6.4.2. By Region
  7. CHAPTER 7. Marketing Strategy Analysis, Distributors
    1. 7.1. Marketing Channel
    2. 7.2. Direct Marketing
    3. 7.3. Indirect Marketing
    4. 7.4. Marketing Channel Development Trend
    5. 7.5. Economic/Political Environmental Change
  8. CHAPTER 8. Report Conclusion
  9. CHAPTER 9. Research Approach & Methodology
    1. 9.1. Report Description
    2. 9.2. Research Scope
    3. 9.3. Research Methodology
      1. 9.3.1. Secondary Research
      2. 9.3.2. Primary Research
      3. 9.3.3. Models
        1. 9.3.3.1. Company Share Analysis Model
        2. 9.3.3.2. Revenue Based Modeling
        3. 9.3.3.3. Research Limitations

        List of Figures

        FIG. 1 Global  Type 1 Diabetes  Market, 2016-2026(USD Million)
        FIG. 2 Global  Type 1 Diabetes  MarketShare, by Insulin Analog, 2019 & 2026 (USD Million)
        FIG. 3 Global Rapid-Acting Insulin Analogs Type 1 Diabetes Market,2016-2026 (USD Million)
        FIG. 4 Global Long-Acting Insulin Analogs Type 1 Diabetes Market,2016-2026 (USD Million)
        FIG. 5 Global Premix Insulin Analogs Type 1 Diabetes Market,2016-2026 (USD Million)
        FIG. 6 Global  Type 1 Diabetes  MarketShare, by Region, 2019 & 2026
        FIG. 7 North America Type 1 Diabetes  Market, 2016-2026
        FIG. 8 U.S. Type 1 Diabetes  Market, 2016-2026
        FIG. 9 Canada Type 1 Diabetes  Market, 2016-2026
        FIG. 10 Europe Type 1 Diabetes  Market, 2016-2026
        FIG. 11 Germany Type 1 Diabetes  Market, 2016-2026
        FIG. 12 France Type 1 Diabetes  Market, 2016-2026
        FIG. 13 U.K. Type 1 Diabetes  Market, 2016-2026
        FIG. 14 Italy Type 1 Diabetes  Market, 2016-2026
        FIG. 15 Spain Type 1 Diabetes  Market, 2016-2026
        FIG. 16 Rest of Europe Type 1 Diabetes  Market, 2016-2026
        FIG. 17 Asia Pacific Type 1 Diabetes  Market, 2016-2026
        FIG. 18 China Type 1 Diabetes  Market, 2016-2026
        FIG. 19 Japan Type 1 Diabetes  Market, 2016-2026
        FIG. 20 India Type 1 Diabetes  Market, 2016-2026
        FIG. 21 South  Korea Type 1 Diabetes  Market, 2016-2026
        FIG. 22 South-East Asia Type 1 Diabetes  Market, 2016-2026
        FIG. 23 Rest of Asia Pacific Type 1 Diabetes  Market, 2016-2026
        FIG. 24 Latin America Type 1 Diabetes  Market, 2016-2026
        FIG. 25 Brazil Type 1 Diabetes  Market, 2016-2026
        FIG. 26 Mexico Type 1 Diabetes  Market, 2016-2026
        FIG. 27 Rest of Latin America Type 1 Diabetes  Market, 2016-2026
        FIG. 28 The Middle-East and Africa Type 1 Diabetes  Market, 2016-2026
        FIG. 29 GCC Countries Type 1 Diabetes  Market, 2016-2026
        FIG. 30 South Africa Type 1 Diabetes  Market, 2016-2026
        FIG. 31 Rest of Middle-East Africa Type 1 Diabetes  Market, 2016-2026
        FIG. 32 Competitor Market Share – Revenue
        FIG. 33 Eli Lilly and Company Revenue and Growth Rate
        FIG. 34 Eli Lilly and Company Market Share
        FIG. 35 Bayer Pharmaceuticals Revenue and Growth Rate
        FIG. 36 Bayer Pharmaceuticals Market Share
        FIG. 37 Sanofi Revenue and Growth Rate
        FIG. 38 Sanofi Market Share
        FIG. 39 Novo Nordisk Revenue and Growth Rate
        FIG. 40 Novo Nordisk Market Share
        FIG. 41 AstraZeneca PLC. Revenue and Growth Rate
        FIG. 42 AstraZeneca PLC. Market Share
        FIG. 43 XOMA Corp. Revenue and Growth Rate
        FIG. 44 XOMA Corp. Market Share
        FIG. 45 DiaVacs Inc. Revenue and Growth Rate
        FIG. 46 DiaVacs Inc. Market Share
        FIG. 47 B.BraunMelsungen AG Revenue and Growth Rate
        FIG. 48 B.BraunMelsungen AG Market Share
        FIG. 49 Biodel Inc. Revenue and Growth Rate
        FIG. 50 Biodel Inc. Market Share
        FIG. 51 Macrogenics Inc. Revenue and Growth Rate
        FIG. 52 Macrogenics Inc. Market Share
        FIG. 53 Takeda Pharmaceutical Revenue and Growth Rate
        FIG. 54 Takeda Pharmaceutical Market Share
        FIG. 55 Market Dynamics
        FIG. 56 Global  Type 1 Diabetes  – Value Chain Analysis
        FIG. 57 Technology Roadmap and Timeline
        FIG. 58 Market Attractiveness Analysis – By Insulin Analog
        FIG. 59 Market Attractiveness Analysis – By Region
        FIG. 60 Market Channel
        FIG. 61 Marketing Channel Development Trend
        FIG. 62 Growth in World Gross Product, 2008-2019

        List of Tables

        TABLE 1 Global  Type 1 Diabetes  Market, 2019& 2026 (USD Million)
        TABLE 2 Global  Type 1 Diabetes  market, by Insulin Analog, 2016-2026 (USD Million)
        TABLE 3 Global  Type 1 Diabetes  market, by Region, 2016-2026 (USD Million)
        TABLE 4 North America Type 1 Diabetes  Market, by Insulin Analog, 2016-2026 (USD Million)
        TABLE 5 Europe Type 1 Diabetes  Market, by Insulin Analog, 2016-2026 (USD Million)
        TABLE 6 Asia Pacific Type 1 Diabetes  Market, by Insulin Analog, 2016-2026 (USD Million)
        TABLE 7 Latin America Type 1 Diabetes  Market, by Insulin Analog, 2016-2026 (USD Million)
        TABLE 8 The Middle-East and Africa Type 1 Diabetes  Market, by Insulin Analog, 2016-2026 (USD Million)
        TABLE 9 Global  Type 1 Diabetes  Market - Company Revenue Analysis 2016-2019 (USD Million)
        TABLE 10 Global  Type 1 Diabetes  Market - Company Revenue Share Analysis 2016-2019(%)
        TABLE 11 Acquisitions and Mergers
        TABLE 12 New Product/Service Launch
        TABLE 13 Research & Development Activities
        TABLE 14 Market Drivers
        TABLE 15 Market Restraints
        TABLE 16 Market Opportunities
        

Key Insights from Primary Research

  • Our primary respondents predict that the global type 1 diabetes market is expected to grow at a CAGR of nearly 5% over the projected period.
  • Rising number of type 1 diabetes patients around the world has driven the consumption of insulin, which has driven the type 1 diabetes market.
  • Our primary respondents also estimate that the global type 1 diabetes market in 2026 is expected to reach a market value of nearly USD 2,800 million.
  • Asia Pacific market is anticipated to grow at the fastest rate over the projected period owing to increasing population and rising number of type 1 diabetic patients.
  • Emerging technologies in healthcare have led to development of artificial pancreas is likely create favorable conditions for new types of diabetic treatments.

Key Recommendations from Analysts

  • Growing health awareness and increased healthcare spending has played a key role in the market growth.
  • According to our analysts, the global type 1 diabetes market was valued at approximately USD 2,000 million in 2019.
  • Based on geography, the North America segment held a share of nearly 35% in the global type 1 diabetes market in 2019.  
  • Our analysts also predict that emergence of gene consulting in predicting type 1 diabetes is likely to create new avenues for the global type 1 diabetes market.
  • Lack of awareness and high cost of treatments such as insulin pump has restricted the type 1 diabetes market growth in developing and underdeveloped countries.

Market Share Analysis by Region

Industry Major Market Players

  • Eli Lilly and Company
  • Bayer Pharmaceuticals
  • Sanofi
  • Novo Nordisk
  • AstraZeneca PLC.
  • XOMA Corp.
  • DiaVacs Inc.
  • B.BraunMelsungen AG
  • Biodel Inc.
  • Macrogenics Inc.
  • Takeda Pharmaceutical

Safe and Secure SSL Encrypted

Choose License Type

Inquiry For Buying

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

have a question

HAVE A QUESTION? Executive will help you find what you are looking for.


REQUEST CUSTOMIZATION

Still haven't found what you're looking for? Speak to our Custom Research Team

Learn More
Facts & Factors provides an array of marketing and business research solutions distinctly designed by our expertise for the clients.
Copyright © 2020 Facts & Factors. All Rights Reserved. Sitemap - Privacy Policy - Terms & Conditions